$80,000 of BIO-RAD LABORATORIES lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to biomedical research and development; Issues related to pathogen surveillance. Issues related to biomedical research and development; Issues related to pathogen surveillance."
You can find more data on corporate lobbying on Quiver Quantitative.
BIO Hedge Fund Activity
We have seen 183 institutional investors add shares of BIO stock to their portfolio, and 255 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WEALTHFRONT ADVISERS LLC removed 1,043,153 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $254,070,344
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC added 852,685 shares (+119.5%) to their portfolio in Q1 2025, for an estimated $207,679,958
- FIRST PACIFIC ADVISORS, LP added 214,705 shares (+136.0%) to their portfolio in Q1 2025, for an estimated $52,293,549
- POINT72 ASSET MANAGEMENT, L.P. removed 212,906 shares (-86.0%) from their portfolio in Q1 2025, for an estimated $51,855,385
- SELECT EQUITY GROUP, L.P. removed 195,478 shares (-42.4%) from their portfolio in Q1 2025, for an estimated $47,610,621
- ARIEL INVESTMENTS, LLC added 164,136 shares (+29.3%) to their portfolio in Q1 2025, for an estimated $39,976,964
- GAMMA INVESTING LLC removed 147,107 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $35,499,861
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIO Analyst Ratings
Wall Street analysts have issued reports on $BIO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/02/2025
- Citigroup issued a "Buy" rating on 05/02/2025
- RBC Capital issued a "Outperform" rating on 05/02/2025
To track analyst ratings and price targets for BIO, check out Quiver Quantitative's $BIO forecast page.
BIO Price Targets
Multiple analysts have issued price targets for $BIO recently. We have seen 4 analysts offer price targets for $BIO in the last 6 months, with a median target of $330.0.
Here are some recent targets:
- Brandon Couillard from Wells Fargo set a target price of $245.0 on 06/09/2025
- Dan Leonard from UBS set a target price of $310.0 on 05/02/2025
- Patrick Donnelly from Citigroup set a target price of $350.0 on 05/02/2025
- Conor McNamara from RBC Capital set a target price of $392.0 on 05/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
